Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella

Vaccine

Volumn 29, Issue 37, 2011, Pages 6327-6334

  Nascimento Silva, Juliana Romualdo ^a   Camacho, Luiz Antonio B ^a   Siqueira, Marilda M ^a   Freire, Marcos de Silva ^a   Castro, Yvone P ^b   Maia, Maria de Lourdes S ^a   Yamamura, Anna Maya Y ^c   Martins, Reinaldo M ^a   Leal, Maria de Luz F ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Programa de Imunizações da Secretaria Distrital de Saúde   (Brazil)

^c Instituto de Technologia em Imunobiologicos   (Brazil)

Author keywords

Brazil; Combined vaccine against measles; Immunogenicity; Reactogenicity; Rubella and mumps; Yellow fever vaccine

Indexed keywords

CAXUMBA; MEASLES MUMPS RUBELLA VACCINE; MMRI; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG FEVER; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNESS; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MEASLES; MUMPS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RUBELLA; SEROCONVERSION; SIDE EFFECT; VACCINATION; VOMITING; YELLOW FEVER;

ANTIBODIES, VIRAL; DATA COLLECTION; DRUG ANTAGONISM; DRUG INTERACTIONS; FEMALE; HUMANS; INFANT; MALE; MEASLES; MEASLES VIRUS; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS; MUMPS VIRUS; QUESTIONNAIRES; RUBELLA; RUBELLA VIRUS; VACCINES, COMBINED; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 80051558772     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.019     Document Type: Article

References (46)

1. Decker M.D., Edwards K.M. Combination vaccines. Vaccines 1999, W.B. Saunders Company, Philadelphia. third ed. S.A. Plotkin, W.A. Orenstein (Eds.).
2. Centers for Disease Control and Prevention General recommendations on immunization: recommendations of the Advisory Committee on Immunizations Practices (ACIP). MMWR 2002, 51(RR-2):1-35.
3. Ministério da Saúde Manual de Procedimentos para Vacinação. Fundação Nacional de Saúde 2001, Ministério da Saúde, Brasília. fourth ed. Programa de Imunizações (Ed.).
4. Centers for Disease Control and Prevention Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010, 59(RR-7).
5. World Health Organization. Fact sheet No. 100; 2001.
6. Grupo Colaborativo do Programa Nacional de Imunizações para o Estudo da Soroconversão pela Vacina contra Febre Amarela Estudo multicêntrico de soroconversão pela vacina contra febre amarela. VII Congresso Brasileiro de Saúde Coletiva 2003, CSCS (Ed.).
7. Camacho L.A.B., Freire M.S., Leal M.L.F., Aguiar S.G., Nascimento J.P., Iguchi T., Omoto T.M., Mann G., Freire M.S., et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saúde Pública 2004, 38(5):671-678.
8. Stefano I., Sato H.K., Pannutti C.S., Omoto T.M., Mann G., Freire M.S., et al. Recent immunization against measles does not interfere with the sero-response of yellow fever vaccine. Vaccine 1999, 17:1042-1046.
9. Monath T.P., Cetron M.S., Teuwen D.E. Yellow fever. Vaccines 2008, W.B. Saunders Elsevier, Philadelphia. fourth ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
10. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program. Vaccine 2007, 25:3118-3123. Collaborative Group for Studies with Yellow Fever Vaccine.
11. Statistical methods for rates and proportions 1981, John Wiley & Sons, New York. second ed. J. Fleiss (Ed.).
12. National Institute for Biological Standards and Control. WHO reference reagent. The 1st international reference preparation for anti-yellow fever serum monkey NIBSC code: YF. Available from: ; 2008 [cited 15.03.2011]. http://www.nibsc.ac.uk/documents/ifu/YF.pdf.
13. WHO Expert Committee on Biological Standardization. Report of a collaborative study to assess the suitability of a replacement for the 2nd International Standard for anti-measles serum. Geneva: World Health Organization; October 23-27, 2006. Report No.: WHO/BS/06.2031. http://whqlibdoc.who.int/hq/2006/WHO_BS_06.2031_eng.pdf.
14. Cohen B.J., Parry R.P., Doblas D., Samuel D., Warrener L., Andrews N., et al. Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay. J Virol Methods 2006, 131(2):209-212.
15. Cohen B.J., Audet S., Andrews N., Beeler J. Plaque reduction neutralization test for measles antibodies: description of standardized laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 2007, 26:59-66. WHO working group on measles plaque reduction neutralization test.
16. Gizurarson S. Clinically relevant vaccine-vaccine interactions. A guide for practitioners. BioDrugs 1998, 9(June (6)):443-453.
17. Rojo C.C., Iglesias M.R., Olvera J., Girón M.A. Study of the immune response engendered by different combined measles, mumps and rubella (MMR) vaccines in an area of Andalusia (Spain). Vaccine 2003, 22:280-286.
18. Klinge J., Korn L.S., Heininger K., Stehr U.K. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age. Vaccine 2000, 18:3134-3140.
19. Tischer A., Gerike E. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella. Vaccine 2000, 18:1382-1392.
20. Meyer H.M., Hostetler D.D., Bernhein B.C., Rogers N.G., Lambin P., Chassary A., et al. Response of Volta children to jet inoculation of combined live measles, smallpox and yellow fever vaccines. Bull World Health Organ 1964, 30:783-794.
21. Felsenfeld O., Wolf R.H., Gyr K., Grant L.S., Dutta N.K. Simultaneous vaccination against cholera and yellow fever. Lancet 1973, I:457-458.
22. Gateff C., Dodin A., Wiart J. A comparison of the serological effects of classical cholera vaccine and of purified fraction, with or without simultaneous yellow fever vaccine. Ann Microbiol (Paris) 1975, 126(2):231-246.
23. Yvonnet B., Coursaget P., Deubel V., Diop-Mar I., Digoutte J.P., Chiron J.P., et al. Simultaneous administration of hepatitis B and yellow fever vaccines. J Med Virol 1986, 19:307-311.
24. Ruben F.L., Smith E.A., Foster S.O. Simultaneous administration of smallpox, measles, yellow fever, and diptheria-pertussis-tetanus antigens to Nigerian children. Bull World Health Organ 1973, 48:175-181.
25. Adu F.D., Omotade O.O., Oyedele O.I., Ikusika O., Odemuyiwa S.O., Onoja A.L. Field trial of combined yellow fever and measles vaccines among children in Nigeria. East Afr Med J 1996, 73(9):579-582.
26. Soula G., Sylla A., Pichard E., Kodio B., Bentejac M.C., Teulières L., et al. Etude d'un noveau vaccin combiné contre la fievre jaune et la rougeol chez des enfants agés de 6 a 24 mois au Mali. Bull Soc Pathol Exot 1991, 84(5):885-897.
27. Mouchon D., Pignon D., Vicens R., Tu-Ha-Thanh, Tekaia F., Teulières L., et al. Étude de la Vaccination Combinée Rougeole-Fièvre Jaune Chez L'Énfant Africaine Agé de 6 a 10 Mois. Bull Soc Pathol Exot 1990, 83:537-551.
28. Lhuillier M., Mazzariol M.J., Zadi S., Le Cam N., Bentejac M.C., Adamowicz L., et al. Study of combined vaccination against yellow fever and measles in infants from six to nine months. J Biol Stand 1989, 17:9-15.
29. Gil A., Gonzalez A., Dal-Re R., Calero J.R. Interference assessment of yellow fever vaccine with the immune response to a single-dose inactivated hepatitis A vaccine (1440 EL.U.). A controlled study in adults. Vaccine 1996, 14(11):1028-1030.
30. Dumas R., Forrat R., Lang J., Farinelli T., Loutan L. Safety and immunogenicity of a new inactivated hepatitis A vaccine and concurrent administration with a typhoid fever vaccine or a typhoid fever+yellow fever vaccine. Adv Ther 1997, 14:160-167.
31. Coursaget P., Bringer L., Bourdil C., Yvonnet B., Chiron J.P., Sarr G., et al. Simultaneous injection of hepatitis B and measles vaccines. Trans R Soc Trop Med Hyg 1991, 85(6):788.
32. Coursaget P., Fritzell B., Blondeau C., Saliou P., Diop-Mar I. Simultaneous injection of plasma-derived or recombinant hepatitis B vaccines with yellow fever and killed polio vaccines. Vaccine 1995, 13(1):109-111.
33. Ambrosch F., Fritzell B., Gregor J., Jonas S., Kollaritsch H., Teulieres L., et al. Combined vaccination against yellow fever and typhoid fever: a comparative trial. Vaccine 1994, 12(7):625-628.
34. Reinhardt B., Jaspert R., Niedrig M., Kostner C., L'age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998, 56(2):159-167.
35. Wheelock E.F., Sibley W.A. Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow fever virus. N Engl J Med 1965, 273(4):194-198.
36. Petralli J.K., Merigan T.C., Wilbur J.R. Action of endogenous interferon against vaccinia infection in children. Lancet 1965, 2:401-405.
37. Umino Y., Saito S., Fukuda A., Hishiyama M., Sugiura A. Improvement in potency assay of measles-mumps-rubella trivalent vaccine: interference between components and measures for its elimination. J Virol Methods 1990, 27(2):159-168.
38. Ratnam S., Gadag V., West T., Burris J., Oates E., Stead F., et al. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles antibody. J Clin Microbiol 1995, 33(4):811-815.
39. Niedrig M., Lademann M., Emmerich P., Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 1999, 4(12):867-871.
40. Suzano C.E., Amaral E., Sato H.K., Papaiordanou P.M. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 2006, 24(9):1421-1426. Campinas Group on Yellow Fever Immunization during Pregnancy.
41. Camacho L.A.B., Freire M.S., Leal M.L.F., Aguiar S.G., Nascimento J.P., Iguchi T., et al. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled. Rev Saúde Pública 2005, 39(3):413-420.
42. Plotkin S.A. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001, 20(1):63-75.
43. Matter L., Kogelschatz K., Germann D. Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. J Infect Dis 1997, 175(4):749-755.
44. Atkinson W., Kroger A., Pickering L.K. General immunization practices. Vaccines 2008, Saunders Elsevier, Philadelphia. fifth ed. S. Plotkin, W. Orenstein, P. Offit (Eds.).
45. Christenson B., Bottiger M. Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults. Vaccine 1994, 12:41-45.
46. Plotkin S.A., Rubin S.A. Mumps vaccine. Vaccines 2008, W.B. Saunders Elsevier, Philadelphia. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).